# AMO959

Source: https://onco.cc/drugs/amo959/  
OnCo record `amo959` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AMO959 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for prostate cancer.

## Summary

AMO959 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Novartis Pharmaceuticals, in prostate cancer. Described in the registry record as a by1298 by101298 dna damage response inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: BY1298; BY101298
- Tags: pipeline; ctgov-ingest; registry-only
- Code: AMO959
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a by1298 by101298 dna damage response inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of AMO959: https://clinicaltrials.gov/search?intr=AMO959

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)
- trials: [A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA](https://onco.cc/trials/nct07226986/)

---
JSON: https://onco.cc/api/v1/entities/amo959.json